Literature DB >> 18538274

[Quality of life after cystectomy: French national survey conducted by the French Association of Urology (AFU), the French Federation of Stoma Patients (FSF) and the French Association of Enterostomy Patients (AFET) in patients with ileal conduit urinary diversion or orthotopic neobladder].

N Mottet1, C Castagnola, P Rischmann, M Deixonne, M Guyot, P Coloby, P Mangin.   

Abstract

OBJECTIVE: National multicentre study based on specific self-administered quality of life questionnaires in patients with Bricker ileal conduit urinary diversion or orthotopic neobladder. MATERIAL AND
METHOD: Questionnaires were distributed by three associations (FSF, AFU, AFET) and comprised general questions and questions specific to the type of diversion. A disability score was also included.
RESULTS: Between September 2003 and March 2004, out of a total of 5739 questionnaires, 909 were returned and 877 were analysed: 738 patients with Bricker ileal conduit and 139 with orthotopic neobladder. The two populations differed at the time of the study (Bricker: 69% of men with a mean age of 70 years, orthotopic neobladder: 95.7% of men with a mean age of 64 years). The mean interval since the operation was seven years. Ninety-four percent of patients with Bricker ileal conduit and 93% of patients with orthotopic neobladder were satisfied or very satisfied with the diversion, despite mean disability scores of 5.2+/-3.7 and 3.1+/-3.6, respectively. A correlation between this score and patient satisfaction (Wilcoxon: p<0.0001) was only observed for patients with a Bricker ileal conduit. This score was significantly related to the presence of urinary incontinence with the two types of diversion. Incontinence was frequent (16.1% with Bricker ileal conduit) and 78% of patients feared episodes of incontinence, mainly due to the appliance. Daytime incontinence was frequent for 18.1% of patients with orthotopic neobladder and 40% of patients used at least one protection per day. Out of the patients with neobladder, 82.6% experienced nocturnal incontinence, interfering with sleep in 31.9% of cases. Sexual disorders and altered bowel habit (40%) were very frequent. Stoma-therapy management was insufficient for Bricker ileal conduit and exceptional after bladder replacement.
CONCLUSION: Cystectomy with either ileal conduit urinary diversion or orthotopic neobladder alters many aspects of the patient's life, but patients finally accept and adapt to their new way of life.

Entities:  

Mesh:

Year:  2008        PMID: 18538274     DOI: 10.1016/j.purol.2008.02.008

Source DB:  PubMed          Journal:  Prog Urol        ISSN: 1166-7087            Impact factor:   0.915


  5 in total

1.  CUA Guideline: Management of ureteral calculi.

Authors:  Michael Ordon; Sero Andonian; Brian Blew; Trevor Schuler; Ben Chew; Kenneth T Pace
Journal:  Can Urol Assoc J       Date:  2015-12-14       Impact factor: 1.862

2.  Perioperative outcomes and complications of intracorporeal vs extracorporeal urinary diversion after robot-assisted radical cystectomy for bladder cancer: a real-life, multi-institutional french study.

Authors:  Louis Lenfant; Gregory Verhoest; Riccardo Campi; Jérôme Parra; Vivien Graffeille; Alexandra Masson-Lecomte; Dimitri Vordos; Alexandre de La Taille; Mathieu Roumiguie; Marine Lesourd; Lionel Taksin; Vincent Misraï; Pietro Grande; Christophe Vaessen; Guillaume Ploussard; Benjamin Granger; Morgan Rouprêt
Journal:  World J Urol       Date:  2018-05-09       Impact factor: 4.226

3.  Efficacy of bladder-preserving therapy for patients with t3b, t4a, and t4b transitional cell carcinoma of the bladder.

Authors:  Jaewoo Cheon; Hyunchul Chung; Jaemann Song
Journal:  Korean J Urol       Date:  2010-08-18

Review 4.  The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer.

Authors:  Christopher M Russell; Amir H Lebastchi; Tudor Borza; Daniel E Spratt; Todd M Morgan
Journal:  Bladder Cancer       Date:  2016-10-27

5.  Conservative treatment of invasive bladder cancer.

Authors:  N J Rene; F B Cury; L Souhami
Journal:  Curr Oncol       Date:  2009-08       Impact factor: 3.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.